AstraZeneca: UBS raises target price
(CercleFinance.com) - UBS reiterates its 'buy' rating on AstraZeneca shares, having increased its target price for them from 9,200 pence to 10,000 pence, a new target price that suggests upside potential of 15% for the UK pharmaceutical company's shares.
"DESTINY-Breast03 has firmly established the antibody-drug conjugate platform with optionality that should allow investors to tolerate ongoing margin discussions," the broker summarised.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"DESTINY-Breast03 has firmly established the antibody-drug conjugate platform with optionality that should allow investors to tolerate ongoing margin discussions," the broker summarised.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.